Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Bonaventura Clotet and Jorge Carrillo.
Bonaventura Clotet
Connection Strength
1.806
Jorge Carrillo
  1. High-dose intravenous immunoglobulins might modulate inflammation in COVID-19 patients. Life Sci Alliance. 2021 09; 4(9).
    View in: PubMed
    Score: 0.240
  2. Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. Biochem Biophys Res Commun. 2021 01 29; 538:187-191.
    View in: PubMed
    Score: 0.228
  3. Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies. Front Immunol. 2018; 9:2429.
    View in: PubMed
    Score: 0.198
  4. Memory B cell dysregulation in HIV-1-infected individuals. AIDS. 2018 Jan 14; 32(2):149-160.
    View in: PubMed
    Score: 0.188
  5. Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target. Front Immunol. 2017; 8:1154.
    View in: PubMed
    Score: 0.183
  6. Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster. Emerg Microbes Infect. 2021 Dec; 10(1):797-809.
    View in: PubMed
    Score: 0.061
  7. Critical Presentation of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection: A Case Report. Open Forum Infect Dis. 2021 Jul; 8(7):ofab329.
    View in: PubMed
    Score: 0.060
  8. Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals. Viruses. 2021 06 12; 13(6).
    View in: PubMed
    Score: 0.059
  9. Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen. Front Pharmacol. 2021; 12:646676.
    View in: PubMed
    Score: 0.059
  10. Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes. Med (N Y). 2021 Mar 12; 2(3):313-320.e4.
    View in: PubMed
    Score: 0.058
  11. SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity. Sci Rep. 2021 01 28; 11(1):2608.
    View in: PubMed
    Score: 0.058
  12. SARS-CoV-2 Cellular Infection and Therapeutic Opportunities: Lessons Learned from Ebola Virus. Membranes (Basel). 2021 Jan 18; 11(1).
    View in: PubMed
    Score: 0.058
  13. Pigs are not susceptible to SARS-CoV-2 infection but are a model for viral immunogenicity studies. Transbound Emerg Dis. 2021 Jul; 68(4):1721-1725.
    View in: PubMed
    Score: 0.057
  14. Outcome of hospitalized patients with COVID-19 pneumonia treated with high-dose immunoglobulin therapy in a prospective case series. Clin Microbiol Infect. 2021 Apr; 27(4):651-652.
    View in: PubMed
    Score: 0.057
  15. Detection of SARS-CoV-2 in a cat owned by a COVID-19-affected patient in Spain. Proc Natl Acad Sci U S A. 2020 10 06; 117(40):24790-24793.
    View in: PubMed
    Score: 0.056
  16. Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection. Mucosal Immunol. 2019 01; 12(1):232-246.
    View in: PubMed
    Score: 0.049
  17. Unexpected synergistic HIV neutralization by a triple microbicide produced in rice endosperm. Proc Natl Acad Sci U S A. 2018 08 14; 115(33):E7854-E7862.
    View in: PubMed
    Score: 0.049
  18. Elevated humoral response to cytomegalovirus in HIV-infected individuals with poor CD4+ T-cell immune recovery. PLoS One. 2017; 12(9):e0184433.
    View in: PubMed
    Score: 0.046
  19. Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif. Sci Rep. 2017 01 13; 7:40800.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.